Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 1

Status

Completed 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5CNS 4NET 1Gastrointestinal 1

Conditions

Glioblastoma 154Brain Neoplasms 73Glioma 69Central Nervous System Neoplasms 50Gliosarcoma 46Astrocytoma 37Melanoma 36Oligodendroglioma 29Neuroblastoma 17Neoplasm Metastasis 14Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 11Sarcoma, Ewing 10Sarcoma 10Neoplasms 10Medulloblastoma 10Recurrence 9Neuroendocrine Tumors 9Lymphoma 8Ependymoma 8Breast Neoplasms 8Small Cell Lung Carcinoma 7Rhabdomyosarcoma 7Diffuse Intrinsic Pontine Glioma 7Colorectal Neoplasms 7Carcinoma, Neuroendocrine 6Adenoma, Islet Cell 6Uveal Melanoma 5Spinal Cord Neoplasms 5Pheochromocytoma 5

Interventions

Temozolomide 5anlotinib 43-Iodobenzylguanidine 4lutetium Lu 177 dotatate 3Specimen Handling 3cabozantinib 2belzutifan 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Everolimus 2Axitinib 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2tipifarnib 1talazoparib 1penpulimab 1pembrolizumab 1pazopanib 1olaparib 1lenvatinib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1fostamatinib 1copper dotatate CU-64 1atezolizumab 1Tamoxifen 1Sunitinib 1Ritonavir 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Pheochromocytoma × Temozolomide × Clear all
NCT04394858 2026-05-13

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
46 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05142241 2025-11-18

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
14 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

Peking Union Medical College Hospital

Phase 2 Unknown
20 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

Peking Union Medical College Hospital

Phase 2 Completed
62 enrolled
CNSEndocrine

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT00869050 2016-07-25

Capecitabine and Temozolomide for Neuroendocrine Cancers

Columbia University

Phase 2 Completed
41 enrolled 9 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Vipoma, Pancreatic Neoplasms, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Gastrinoma, Carcinoma, Medullary, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡